Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Ferreira, BV"'
Autor:
Sampaio, LR, Oliveira, VS, Viana, MA, Ferreira, BV, Melo, MML, Silva, TMCE, Ribeiro, RCO, Dias, RDB, Magalhães, SMM, Pinheiro, RF
Publikováno v:
In Hematology, Transfusion and Cell Therapy October 2022 44 Supplement 2:S201-S201
Autor:
Grenhas M; Myeloma Lymphoma Research Group, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, 1400-038 Lisbon, Portugal., Lopes R; Myeloma Lymphoma Research Group, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, 1400-038 Lisbon, Portugal.; Faculty of Medicine, University of Lisbon, 1649-028 Lisbon, Portugal., Ferreira BV; Myeloma Lymphoma Research Group, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, 1400-038 Lisbon, Portugal.; Hemato-Oncology Department, Champalimaud Foundation, 1400-038 Lisbon, Portugal., Barahona F; Myeloma Lymphoma Research Group, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, 1400-038 Lisbon, Portugal.; Faculty of Medical Sciences, NOVA Medical School, 1169-056 Lisbon, Portugal., João C; Myeloma Lymphoma Research Group, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, 1400-038 Lisbon, Portugal.; Hemato-Oncology Department, Champalimaud Foundation, 1400-038 Lisbon, Portugal.; Faculty of Medical Sciences, NOVA Medical School, 1169-056 Lisbon, Portugal., Carneiro EA; Myeloma Lymphoma Research Group, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, 1400-038 Lisbon, Portugal.
Publikováno v:
International journal of molecular sciences [Int J Mol Sci] 2024 Aug 03; Vol. 25 (15). Date of Electronic Publication: 2024 Aug 03.
High PD-L1 expression is associated with unfavorable clinical features in myelodysplastic neoplasms.
Autor:
Sampaio LR; Universidade Federal do Ceará (UFC), Fortaleza, CE, Brazil; Núcleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Fortaleza, CE, Brazil., Viana MA; Universidade Federal do Ceará (UFC), Fortaleza, CE, Brazil; Núcleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Fortaleza, CE, Brazil., de Oliveira VS; Universidade Federal do Ceará (UFC), Fortaleza, CE, Brazil; Núcleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Fortaleza, CE, Brazil., Ferreira BV; Universidade Federal do Ceará (UFC), Fortaleza, CE, Brazil; Núcleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Fortaleza, CE, Brazil., Melo MML; Universidade Federal do Ceará (UFC), Fortaleza, CE, Brazil; Núcleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Fortaleza, CE, Brazil., de Oliveira RTG; Universidade Federal do Ceará (UFC), Fortaleza, CE, Brazil; Núcleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Fortaleza, CE, Brazil., Borges DP; Universidade Federal do Ceará (UFC), Fortaleza, CE, Brazil; Núcleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Fortaleza, CE, Brazil., Magalhãesa SMM; Universidade Federal do Ceará (UFC), Fortaleza, CE, Brazil; Núcleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Fortaleza, CE, Brazil., Pinheiro RF; Universidade Federal do Ceará (UFC), Fortaleza, CE, Brazil; Núcleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Fortaleza, CE, Brazil. Electronic address: ronaldpinheiro@pq.cnpq.br.
Publikováno v:
Hematology, transfusion and cell therapy [Hematol Transfus Cell Ther] 2024 Apr-Jun; Vol. 46 (2), pp. 146-152. Date of Electronic Publication: 2023 Jun 05.
Autor:
Lopes R; Myeloma Lymphoma Research Group, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, Lisbon, Portugal.; Faculty of Medicine, University of Lisbon, Lisbon, Portugal., Caetano J; Myeloma Lymphoma Research Group, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, Lisbon, Portugal.; Hemato-Oncology Department, Champalimaud Foundation, Lisbon, Portugal.; Faculty of Medical Sciences, NOVA Medical School (NMS), Lisbon, Portugal., Barahona F; Myeloma Lymphoma Research Group, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, Lisbon, Portugal.; Faculty of Medical Sciences, NOVA Medical School (NMS), Lisbon, Portugal., Pestana C; Myeloma Lymphoma Research Group, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, Lisbon, Portugal.; Centre of Statistics and Its Applications, Faculty of Sciences, University of Lisbon, Lisbon, Portugal., Ferreira BV; Myeloma Lymphoma Research Group, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, Lisbon, Portugal.; Hemato-Oncology Department, Champalimaud Foundation, Lisbon, Portugal.; Faculty of Medical Sciences, NOVA Medical School (NMS), Lisbon, Portugal., Lourenço D; Myeloma Lymphoma Research Group, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, Lisbon, Portugal.; Faculty of Medicine, University of Coimbra, Coimbra, Portugal., Queirós AC; Myeloma Lymphoma Research Group, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, Lisbon, Portugal., Bilreiro C; Faculty of Medical Sciences, NOVA Medical School (NMS), Lisbon, Portugal.; Neural Plasticity and Neural Activity Laboratory, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, Lisbon, Portugal.; Radiology Department, Champalimaud Foundation, Lisbon, Portugal., Shemesh N; Neural Plasticity and Neural Activity Laboratory, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, Lisbon, Portugal., Beck HC; Centre for Clinical Proteomics, Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark., Carvalho AS; Computational and Experimental Biology, Chronic Diseases Research Centre (CEDOC); NOVA Medical School (NMS), Lisbon, Portugal., Matthiesen R; Computational and Experimental Biology, Chronic Diseases Research Centre (CEDOC); NOVA Medical School (NMS), Lisbon, Portugal., Bogen B; Institute of Immunology, University of Oslo and Oslo University Hospital, Oslo, Norway., Costa-Silva B; Systems Oncology, Champalimaud Physiology and Cancer Programme, Champalimaud Foundation, Lisbon, Portugal., Serre K; Molecular Medicine Institute-Laço Hub, Instituto de Medicina Molecular João Lobo Antunes, Lisbon, Portugal., Carneiro EA; Myeloma Lymphoma Research Group, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, Lisbon, Portugal., João C; Myeloma Lymphoma Research Group, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, Lisbon, Portugal.; Hemato-Oncology Department, Champalimaud Foundation, Lisbon, Portugal.; Faculty of Medical Sciences, NOVA Medical School (NMS), Lisbon, Portugal.
Publikováno v:
Frontiers in immunology [Front Immunol] 2022 Jul 07; Vol. 13, pp. 909880. Date of Electronic Publication: 2022 Jul 07 (Print Publication: 2022).
Autor:
Ferreira BV; Myeloma Lymphoma Research Group, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, Lisbon, Portugal.; NOVA Medical School (NMS), NOVA University Lisbon, Lisbon, Portugal.; Hemato-Oncology Unit, Champalimaud Clinical Centre, Champalimaud Foundation, Lisbon, Portugal., Carneiro EA; Myeloma Lymphoma Research Group, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, Lisbon, Portugal., Pestana C; Myeloma Lymphoma Research Group, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, Lisbon, Portugal.; Centre of Statistics and its Applications, Faculty of Sciences, University of Lisbon, Lisbon, Portugal., Barahona F; Myeloma Lymphoma Research Group, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, Lisbon, Portugal.; NOVA Medical School (NMS), NOVA University Lisbon, Lisbon, Portugal., Caetano J; Myeloma Lymphoma Research Group, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, Lisbon, Portugal.; NOVA Medical School (NMS), NOVA University Lisbon, Lisbon, Portugal.; Hemato-Oncology Unit, Champalimaud Clinical Centre, Champalimaud Foundation, Lisbon, Portugal., Lopes R; Myeloma Lymphoma Research Group, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, Lisbon, Portugal.; Faculty of Medicine, University of Lisbon, Lisbon, Portugal., Lúcio P; Hemato-Oncology Unit, Champalimaud Clinical Centre, Champalimaud Foundation, Lisbon, Portugal., Neves M; Hemato-Oncology Unit, Champalimaud Clinical Centre, Champalimaud Foundation, Lisbon, Portugal., Beck HC; Centre for Clinical Proteomics, Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark., Carvalho AS; NOVA Medical School (NMS), Faculdade de Ciências Médicas (FCM), Universidade Nova de Lisboa, Lisboa, Portugal., Matthiesen R; NOVA Medical School (NMS), Faculdade de Ciências Médicas (FCM), Universidade Nova de Lisboa, Lisboa, Portugal., Costa-Silva B; Systems Oncology Group, Champalimaud Physiology and Cancer Programme, Champalimaud Foundation, Lisbon, Portugal., João C; Myeloma Lymphoma Research Group, Champalimaud Experimental Clinical Research Programme, Champalimaud Foundation, Lisbon, Portugal.; NOVA Medical School (NMS), NOVA University Lisbon, Lisbon, Portugal.; Hemato-Oncology Unit, Champalimaud Clinical Centre, Champalimaud Foundation, Lisbon, Portugal.
Publikováno v:
Frontiers in oncology [Front Oncol] 2022 Jun 21; Vol. 12, pp. 860849. Date of Electronic Publication: 2022 Jun 21 (Print Publication: 2022).
Autor:
Lopes R; Lymphoma and Myeloma Research Programme, Champalimaud Centre for the Unknown, 1400-038 Lisbon, Portugal.; Faculty of Medicine, University of Lisbon, 1649-028 Lisbon, Portugal., Ferreira BV; Lymphoma and Myeloma Research Programme, Champalimaud Centre for the Unknown, 1400-038 Lisbon, Portugal.; Faculty of Medical Sciences, NOVA Medical School, 1169-056 Lisbon, Portugal., Caetano J; Lymphoma and Myeloma Research Programme, Champalimaud Centre for the Unknown, 1400-038 Lisbon, Portugal.; Faculty of Medical Sciences, NOVA Medical School, 1169-056 Lisbon, Portugal.; Hemato-Oncology Department, Champalimaud Centre for the Unknown, 1400-038 Lisbon, Portugal., Barahona F; Lymphoma and Myeloma Research Programme, Champalimaud Centre for the Unknown, 1400-038 Lisbon, Portugal.; Faculty of Medical Sciences, NOVA Medical School, 1169-056 Lisbon, Portugal., Carneiro EA; Lymphoma and Myeloma Research Programme, Champalimaud Centre for the Unknown, 1400-038 Lisbon, Portugal., João C; Lymphoma and Myeloma Research Programme, Champalimaud Centre for the Unknown, 1400-038 Lisbon, Portugal.; Faculty of Medical Sciences, NOVA Medical School, 1169-056 Lisbon, Portugal.; Hemato-Oncology Department, Champalimaud Centre for the Unknown, 1400-038 Lisbon, Portugal.
Publikováno v:
Cancers [Cancers (Basel)] 2021 Mar 11; Vol. 13 (6). Date of Electronic Publication: 2021 Mar 11.
Autor:
Ferreira J Júnior; Applied Computing Lab, Instituto Tecnológico Vale, Belém - PA, Brazil.; Institute of Exact and Natural Sciences, Federal University of Pará, Belém - PA, Brazil., Carvalho E; Applied Computing Lab, Instituto Tecnológico Vale, Belém - PA, Brazil.; SENAI Institute of Innovation - Mineral Technologies, Belém - PA, Brazil., Ferreira BV; Applied Computing Lab, Instituto Tecnológico Vale, Belém - PA, Brazil.; SENAI Institute of Innovation - Mineral Technologies, Belém - PA, Brazil., de Souza C; Applied Computing Lab, Instituto Tecnológico Vale, Belém - PA, Brazil.; Institute of Exact and Natural Sciences, Federal University of Pará, Belém - PA, Brazil., Suhara Y; Recruit Institute of Technology, Mountain View - CA, United States of America., Pentland A; Media Lab, Massachusetts Institute of Technology, Cambridge - MA, United States of America., Pessin G; Applied Computing Lab, Instituto Tecnológico Vale, Belém - PA, Brazil.; Institute of Exact and Natural Sciences, Federal University of Pará, Belém - PA, Brazil.
Publikováno v:
PloS one [PLoS One] 2017 Apr 10; Vol. 12 (4), pp. e0174959. Date of Electronic Publication: 2017 Apr 10 (Print Publication: 2017).
Autor:
Cabral HW; Post-Doctoral degree in Neuroscience - Adjunct Professor of Medicine and Permanent Professor for the Masters Program in Public Policies and Local Development at Escola Superior de Ciências da Santa Casa de Misericórdia de Vitória (Emescam), Vitória, ES, Brazil., Andolphi BF; MD at Emescam, Vitória, ES, Brazil., Ferreira BV; MD at Emescam, Vitória, ES, Brazil., Alves DC; MD at Emescam, Vitória, ES, Brazil., Morelato RL; PhD in Physiological Sciences - Head of the Geriatric Service and Adjunct Professor at Emescam, Vitória, ES, Brazil., Chambo A Filho; PhD in Medicine - Full Professor of Gynecology and Obstetrics, Emescam, Vitória, ES, Brazil., Borges LS; PhD, degree in Sciences. Post-Doctoral research at Université Paris Sud 11, Paris, France.
Publikováno v:
Revista da Associacao Medica Brasileira (1992) [Rev Assoc Med Bras (1992)] 2016 Jul; Vol. 62 (4), pp. 368-76.
Autor:
Ferreira BV; Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London SE1 9RT, UK., Harrison C; Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London SE1 9RT, UK. Electronic address: Claire@Harrisonlong.co.uk.
Publikováno v:
Best practice & research. Clinical haematology [Best Pract Res Clin Haematol] 2014 Jun; Vol. 27 (2), pp. 187-95. Date of Electronic Publication: 2014 Jul 18.
Autor:
de Oliveira IM; Department of Functional Biology and Health Sciences, Faculty of Biology, University of Vigo, Vigo, Spain. irismacoli@uvigo.es, Nunes BV, Barbosa DR, Pallares AM, Faro LR
Publikováno v:
Toxicology letters [Toxicol Lett] 2010 Feb 15; Vol. 192 (3), pp. 294-7. Date of Electronic Publication: 2009 Nov 10.